Opendata, web and dolomites

PROT-RESIST SIGNED

Toward the Commercialization of a Proteolytically Resistant APPI Variant for Inhibiting Metastasis in Prostate and Pancreatic Cancer

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PROT-RESIST project word cloud

Explore the words cloud of the PROT-RESIST project. It provides you a very rough idea of what is the project "PROT-RESIST" about.

prostate    erc    promotes    input    binding    enhanced    leaders    human    potency    market    directed    medical    indications    opinion    picomolar    specificity    carry    appi    adjuvant    cell    clinical    generate    feedback    feasible    experts    prototype    designated    deaths    poc    standard    planning    antimetastatic    treatments    contribution    exhibits    metastatic    involvement    domain    neoadjuvant    tumors    inhibitor    confirm    tumor    kunitz    site    resistance    beta    therapies    protease    soc    primary    cancer    windows    therapy    cancers    agents    ongoing    affinity    translation    evolution    body    decreasing    protocols    distal    scaffold    engineered    serine    therapeutic    pancreatic    nevertheless    urgent    translated    optimization    models    progression    proteolytic    clearance    commercialization    ip    stage    mesotrypsin    preclinical    precursor    perform    anti    consequently    clinicians    direct    stg    protein    parallel    care    invasion    attractive    metastasis    amyloid    intervention    final    3m   

Project "PROT-RESIST" data sheet

The following table provides information about the project.

Coordinator
BEN-GURION UNIVERSITY OF THE NEGEV 

Organization address
address: .
city: BEER SHEVA
postcode: 84105
website: www.bgu.ac.il

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 0 €
 EC max contribution 150˙000 € (0%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2019-PoC
 Funding Scheme ERC-POC-LS
 Starting year 2019
 Duration (year-month-day) from 2019-11-01   to  2021-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    BEN-GURION UNIVERSITY OF THE NEGEV IL (BEER SHEVA) coordinator 150˙000.00

Map

 Project objective

Distal site tumor metastasis is the leading cause of prostate- and pancreatic-cancer-related deaths; nevertheless, standard-of-care (SoC) treatments and other targeted therapies under development are based on their activity against the primary tumors rather than on their anti-metastatic activity. There is consequently an urgent medical need for new agents targeting the metastatic process. In prostate and pancreatic cancer models, the serine protease mesotrypsin promotes tumor invasion and metastasis, making it an attractive target for therapeutic intervention. In our ERC StG project, we used directed evolution to generate a novel prototype mesotrypsin inhibitor, designated APPI-3M, which is based on the human amyloid β-protein precursor Kunitz protease inhibitor domain (APPI) scaffold. This inhibitor has picomolar affinity, enhanced binding specificity and improved proteolytic resistance to mesotrypsin and exhibits high potency in cell-based and preclinical models of prostate cancer invasion and metastasis. In this PoC proposal, we propose to perform final lead optimization (particularly decreasing body clearance) of APPI-3M towards its commercialization for clinical translation as an antimetastatic therapeutic adjuvant, with the direct involvement in the planning stage of clinicians and other key opinion leaders in the field. The feedback of these experts is expected to confirm the need to address the problem of metastatic progression and to identify potential indications and therapeutic windows for the use of APPI-3M as a neoadjuvant in prostate and pancreatic cancers. This input will be translated into feasible preclinical studies to demonstrate the contribution of APPI-3M therapy to currently ongoing SoC protocols for prostate and pancreatic cancers. In parallel, we will carry out the in-depth market and IP analyses needed for the commercialization of the engineered protein for therapeutic applications.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PROT-RESIST" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PROT-RESIST" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

evolSingleCellGRN (2019)

Constraint, Adaptation, and Heterogeneity: Genomic and single-cell approaches to understanding the evolution of developmental gene regulatory networks

Read More  

IMMUNOTHROMBOSIS (2019)

Cross-talk between platelets and immunity - implications for host homeostasis and defense

Read More  

HEIST (2020)

High-temperature Electrochemical Impedance Spectroscopy Transmission electron microscopy on energy materials

Read More